Skip to main content
. 2014 Dec 17;7:7–17. doi: 10.2147/IJWH.S73944

Table 2.

Ibandronate fracture-reduction pivotal studies

Frequency and route Dose Fracture risk, relative risk reduction, % (P-value)
Vertebral fracture
Non-vertebral fracture
1 year 2 years 3 years 2 years 3 years
Oral
Daily 2.5 mg 59 (MVF) (0.0561)13
59 (SVF) (0.0164)14
61 (MVF) (0.0006)13
59 (SVF) (0.0004)14
62 (MVF) (0.0001)13
49 (CVF) (0.0117)13
59 (SVF) (0.0001)14
69 (0.013)13 (subgroup T-score <−3.0)
Intermittent 20 mg every other day for 12 doses every 3 months 56 (MVF) (0.0017)13 50 (MVF) (0.0006)13
48 (CVF) (0.0143)13
37 (0.22)13 (subgroup T-score <−3.0)
ACE
Pooled analysis (150 mg orally monthly and intravenous doses) ACE ≥10.8 mg 29 (0.041)22
38 (0.038)23

Abbreviations: ACE, annual cumulative exposure; CVF, clinical vertebral fractures; MVF, morphometric vertebral fractures; SVF, severe vertebral fractures.